Skip to main content

Market Overview

Castle Biosciences: Q4 Earnings Insights


Shares of Castle Biosciences (NASDAQ:CSTL) were flat in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share were down 254.55% year over year to ($0.17), which missed the estimate of ($0.12).

Revenue of $17,299,000 declined by 1.91% from the same period last year, which beat the estimate of $15,740,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Castle Biosciences hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: Mar 08, 2021

Time: 04:30 PM

ET Webcast URL:


52-week high: $107.69

Company's 52-week low was at $21.01

Price action over last quarter: Up 36.51%

Company Profile

Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.


Related Articles (CSTL)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings